Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Genetically engineered NK/T cell therapies show promise in cancer treatment due to precise targeting and efficacy.
• Current limitations include the immunosuppressive tumor microenvironment, effector cell exhaustion, off-target effects, manufacturing complexity, and poor cell infiltration.

Purpose of the Study:

• To review the progress of CRISPR/Cas9 applications in cancer immunotherapy.
• To discuss the potential of CRISPR/Cas9 in overcoming current limitations of engineered NK/T cell therapies.

Main Methods:

• Review of current scientific literature on CRISPR/Cas9 applications in cancer immunotherapy.
• Analysis of CRISPR/Cas9's role in enhancing NK/T cell therapies.

Main Results:

• CRISPR/Cas9 technology demonstrates significant potential in addressing challenges associated with engineered effector cell therapies.
• The technology offers novel strategies to improve efficacy and availability of these advanced cancer treatments.

Conclusions:

• CRISPR/Cas9 is a powerful tool for advancing cancer immunotherapy by improving engineered NK/T cell therapies.
• Further research into NK/T cell applications, gene delivery, efficiency, and implications is crucial for clinical translation.